| Literature DB >> 23148371 |
Luisa Cimmino1, Iannis Aifantis.
Abstract
In this issue of Cancer Discovery, Geng and colleagues report on their use of a combination of promoter cytosine methylation profiling with gene expression and ChIP sequencing to elucidate molecular signatures of adult B-acute lymphoblastic leukemia patient samples with BCR-ABL1, E2A-PBX1, and MLL rearrangements. The unique epigenetic and gene expression signatures of these clinically unfavorable B-ALL subtypes identify novel biomarkers and provide a strong rationale for repurposing existing therapies to treat these molecularly distinct diseases. ©2012 AACR.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23148371 PMCID: PMC4307588 DOI: 10.1158/2159-8290.CD-12-0435
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397